Serum Institute of India (SII has said the company is going to produce 3 to 4 million doses of the experimental Covid-19 vaccine candidate developed by Oxford University and AstraZeneca by December this year.
Adar Poonawalla, SII’s chief executive officer, said Covishield is the first Covid-19 vaccine they hope to launch if the trials are successful both in the UK and in India.
SII, the largest vaccine manufacturer in the world, has been chosen by Oxford and its AstraZeneca to manufacture the vaccine once it today…maybe even sooner.”
“The vaccine under development will be injected into 4,000-5,000 volunteers in Pune and Mumbai, which have high rates of coronavirus infections, as part of the crucial phase three of the trial which will determine if the antidote can be introduced in the market or not,” he said.
Poonawalla said unlike the exclusion of older people in the initial phase of trials at Oxford, the Indian trials will include elderly people and health workers as well because the initial phase has conclusively proven the safety of the vaccine.
Other than the process of applying for trials and having actual trials on humans in India, the company will also be applying for special permission to start manufacturing the vaccine in the country, which exposes it to a commercial risk if the vaccine fails at the last stage, he said.
The company will manufacture up to 70 million doses of the vaccine per month up to October as part of the special permission and plans to take it up to 100 million per month by December so that it is ready to hit the market once the final approvals are in place.
If this goes to plan, the phase three trials will take two months after the patients get injected and the vaccine gets a final nod by November, he said, adding that in such a scenario, it can get introduced either in the “first quarter of 2021”.
The company has already manufactured around 2-3 million doses of the vaccine for getting the process correct and also stabilising its machinery, Poonawalla said, clarifying that these will never be used on humans.
“If you look at the process right now, the risk of the opex (operating expenditure which we are putting in is more than $200 million. If this vaccine fails, we will be down (by $200 million,” he said, adding the expenses exclude the opportunity cost of using the same facility for some other purpose.
Poonawalla also said SII is looking at external investors for the vaccine-related endeavour and added that it has tie-ups with five other vaccine candidates which will be housed into a separate step-down subsidiary, where the family will dilute its stake by 15-20%.
Apart from the five tie-ups already forged, SII is in talks with two other candidates, he said, adding that a manufacturing plant with a capacity to produce 1 billion units of the vaccine per year will also get housed in the subsidiary.
He said it is extremely likely that the Covid-19 vaccine would require two or more doses, like in the case of antidotes for measles and other diseases.
“We have got a lot on the line and bet big on this (Oxford-AstraZeneca candidate. And we really hope it works,” he added.
(With agency inputs